Visterra to Present Data on VIS513, its Humanised mAb That Targets a Conserved Site on the Dengue Virus E Protein

Visterra, Inc., a biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics, has announced that new preclinical data for VIS513 will be presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington DC.

“VIS513 was developed using Visterra’s innovative and proprietary technology and we are very encouraged by these new data which show the potential of VIS513 to broadly neutralise all four dengue virus serotypes,” said Brian J.G. Pereira, MD, President and Chief Executive Officer of Visterra. “Currently there is no specific treatment for dengue and prevention depends solely on limiting or eradicating mosquitoes that transmit the virus. VIS513 has demonstrated a rapid reduction in viral titers after a single systemic administration, which supports its potential use as a treatment for dengue virus infection. Based on these data, we plan to advance its development and enter the clinic in 2015.”

The poster presentation scheduled for ICAAC is: “Design of a Broadly Neutralizing Antibody Targeting Dengue Virus E Protein Domain III,” [V-1819]

Monday, 8 September 2014, 11:00 am–1:00 pm, Poster Session Respiratory and Other Viruses: Novel Treatments, Resistance, and Clinical Observations (Exhibit Hall B/Walter E. Washington Convention Center)